TTP 273

Drug Profile

TTP 273

Alternative Names: TTP-273

Latest Information Update: 13 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator vTv Therapeutics
  • Developer vTv Therapeutics LLC
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 11 Jun 2017 Updated adverse events data from the phase II LOGRA trial in Type-2 diabetes mellitus released by vTv Therapeutics
  • 01 Jan 2017 vTv Therapeutics completes the phase II LOGRA trial for Type-2 diabetes mellitus in USA (NCT02653599)
  • 14 Dec 2016 TTP 273 is available for licensing as of 14 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top